At the heart of the problem is growing resistance to the drug artemisinin, the mainstay of treatment worldwide for the most dangerous form of malaria. Signs of resistance were first reported in western Cambodia, and the problem has now also been identified in Laos, Myanmar, Thailand and Vietnam.
The number of malaria cases in these areas is relatively low, but experts predict that if artemisinin resistance was to take a hold on the Indian subcontinent or, worse still, in sub-Saharan Africa, the consequences could be incalculable. The gains of over two decades of global struggles against malaria could possibly be undone and hundreds of millions of dollars in investment squandered.
Current headlines describing the consequences of hesitating in response to infectious diseases offer some timely advice. Asia must launch an urgent, all-out offensive against malaria and drug resistance or suffer the after-effects for years to come. A collective, high-level engagement of governments across the Asia-Pacific region is essential, as well as that of key malaria partners and funders.
All eyes are turning to the ninth East Asian Summit (EAS), to be held next week in Naypyidaw, the newly built capital of Myanmar. With the agenda yet to be finalised, health experts are pushing for recognition by the region’s leaders that malaria poses more than just a health threat — if unchecked, it could quickly become a drag on regional economic development.
Australia and Vietnam are leading campaigners in the anti-malaria cause. They will be urging colleagues attending the summit to collectively adopt an ambitious, yet feasible target: complete elimination of the disease in Asia Pacific in the next 15 years.
Prime Minister Tony Abbott of Australia and Prime Minister Nguyen Tan Dung of Vietnam are co-chairs of the Asia Pacific Leaders Malaria Alliance (APLMA), a first-of-its-kind grouping of heads of government devoted to battling malaria. The Alliance, hosted by the Asian Development Bank (ADB), is focusing on tackling the problem of shrinking financial support for the malaria effort and on improving access to highest quality malaria medicines.
Myanmar, as the current chair of ASEAN (the 10-nation Association of Southeast Asian Nations) and host of the East Asian Summit in November, has a pivotal role in setting the agenda of the Naypyidaw gathering. While ASEAN economic integration — scheduled for next year — is likely to dominate discussions, Myanmar is expected to show that after years of isolation, it is also now emerging as a regional leader in the fight against malaria.
And with good cause. Of the countries in the Greater Mekong Sub-region, Myanmar has the highest overall malaria burden. The disease is highly endemic across the country, especially towards the eastern and western border areas. At the same time, the emergence of artemisinin resistance along the Myanmar-Thailand border is proving to be an unwelcome obstacle in efforts to bring the disease under control.
The fact that resistance to artemisinin has extended from its presumed point of origin, at the Thailand–Cambodia border, to as far west as Myanmar is a particular cause for concern. If resistance reaches India, as has happened with previous front-line antimalarial medicines, the task of controlling its global spread will be exponentially more difficult.
Myanmar’s malaria response has been vigorous, including through the Myanmar Artemisinin Resistance Containment (MARC) initiative, which focuses on malaria case detection and management in hard-to-reach areas, and scaling up of rapid diagnostic tests. Nevertheless, Myanmar also knows that Asia — and the global health community — is looking towards the summit as an opportunity to accelerate the regional response to this rapidly evolving threat.
Benjamin Rolfe is executive secretary, Asia Pacific Leaders Malaria Alliance
Remarks: The OpEd was published in The Hindustan Times on 6 November 2014, view original source.